| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4216014 | Revue des Maladies Respiratoires Actualités | 2013 | 5 Pages |
Abstract
Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, secondary to occupational asbestos exposure. Clinical and radiological signs are unspecific. The diagnosis of MPM is based on histology on biopsies best obtained by thoracoscopy. Prophylactic irradiation of chest scars and drains is validated by French guidelines. Surgery, extrapleural pneumonectomy or pleurectomy/decortication, is not recommended outside a clinical trial. Firstline chemotherapy with pemetrexed remains the standard treatment. Bevacizumab is currently tested in an ongoing randomized phase 3 trial, MAPS, ending in late 2013.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
J. Margery, W. Gaspard, I. Ngampolo, H. Souhi, H. Le Floch, F. Rivière, C. Marotel, D. Planchard, F. Vaylet,